SELECTing the right patients: upadacitinib in GCA Dr. Brian Jaros reports on abstract 1695, presented at #ACR24. https://t.co/x8lLTviOKk https://t.co/yXwwrdgIyu

Assessment of axSpA Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24. https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq

PsA Ultrasound Updates Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR24. https://t.co/DZBe8uNpJS https://t.co/wIS1hUZnAS

#ACR Best 2024 - Day 4 Although the last day of #ACR24 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today. As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.… https://t.co/ws9BOxkZft https://t.co/trMevuvvyX

Methotrexate to Prevent RA, Clear as Mud Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3

Predicting flares in rheumatic diseases with machine learning Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM

Changing Mindsets about Methotrexate Side Effects Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24. https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr

How New Medications are Reframing Imaging Abnormalities in axSpA Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG

Where there’s smoke, there’s flare: how pollution fuels RA The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24 https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa

Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/x662FbdNoR https://t.co/uvMPHpmRHZ

Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). https://t.co/JD6z4VTfJn #ACR24 https://t.co/7gEK8acRl0

💊Litifilimab- another new molecule for SLE Anti BDCA2 🎯 In cutaneous lupus👉 👉Decrease CLASI score 👉Decrease IFN induced MxA expression #ACR2024 #ACRAmbassador https://t.co/AeJOGhVXIR